BR9815170A - "método de obter composto aplicável no tratamento de asma em mamìferos" - Google Patents
"método de obter composto aplicável no tratamento de asma em mamìferos"Info
- Publication number
- BR9815170A BR9815170A BR9815170-3A BR9815170A BR9815170A BR 9815170 A BR9815170 A BR 9815170A BR 9815170 A BR9815170 A BR 9815170A BR 9815170 A BR9815170 A BR 9815170A
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- straight
- optionally substituted
- alkylene groups
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 16
- 208000006673 asthma Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 title 1
- 125000002947 alkylene group Chemical group 0.000 abstract 15
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 10
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 9
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 5
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 5
- 229910052799 carbon Inorganic materials 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 229910052757 nitrogen Inorganic materials 0.000 abstract 5
- 229910052760 oxygen Inorganic materials 0.000 abstract 5
- 229910052717 sulfur Inorganic materials 0.000 abstract 5
- 230000009435 amidation Effects 0.000 abstract 1
- 238000007112 amidation reaction Methods 0.000 abstract 1
- 238000005576 amination reaction Methods 0.000 abstract 1
- 238000006477 desulfuration reaction Methods 0.000 abstract 1
- 230000023556 desulfurization Effects 0.000 abstract 1
- 238000006073 displacement reaction Methods 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 230000026030 halogenation Effects 0.000 abstract 1
- 238000005658 halogenation reaction Methods 0.000 abstract 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 abstract 1
- 238000006722 reduction reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Compounds Of Unknown Constitution (AREA)
Abstract
Patente de invenção de "MéTODO DE OBTER COMPOSTO APLICáVEL NO TRATAMENTO DE ASMA EM MAMìFEROS". A invenção se refere mais especificamente compostos que sejam mais efetivos inibidores de PDE IV que aqueles da técnica anterior. O composto em questão apresenta a fórmula geral (I) : onde: Z é selecionado do grupo consistindo de grupos de alquileno tais como CH2, CH2CH2CH(CH3), grupos alquilenos tais como CH=CH; grupos alquileno tais como C <MU>= <MV>C ; e NH, N(C1-C3 alquila) , O,S,C(O)CH2 e OCH2; R1 e R2 são independentemente selecionados do grupo consistindo de hidrogênio e uma alquila de cadeia reta ou ramificada C1-C8 ou cicloalquila C3-C8; R3 é uma alquila de cadeia reta ou ramificada; R4 é uma cicloalquila C3-C10 opcionalmente substituída com OH ou uma cicloalquila opcionalmente substituída com OH, e R8 é uma alquila de cadeia reta ou ramificada ou uma cicloalquila C3-C8 opcionalmente substituída com OH. Segundo a invenção o composto é obtido pelas seguintes etapas: (a) reagir um composto da fórmula (II) : onde Z, R3 e R4 são como acima definido, com uma quantidade efetiva de um éster para formas um composto da fórmula (III) : onde Z é selecionado do grupo consistindo de grupos de alquileno tais como CH2, CH2CH2CH(CH3), grupos alquilenos tais como CH=CH; grupos alquileno tais como C <MU>= <MV>C ; e NH, N (C1-C3 alquila),O,S,C (O) CH2 e OCH2;R1 e R2 são independentemente selecionados do grupo consistindo de hidrogênio e uma alquila de cadeia reta ou ramificada C1-C8 ou cicloalquila C3-C8; R3 é uma alquila de cadeia reta ou ramificada; R4 é uma cicloalquila C3-C10 opcionalmente substituída com OH ou uma cicloalquila opcionalmente substituída com OH, e (b) submeter dito composto (III) a etapas sucessivas de aminação, redução e amidação para formar o composto(IV) ; onde: Z é selecionado do grupo consistindo de grupos de alquileno tais como CH2, CH2CH2CH (CH3), grupos alquilenos tais como CH=CH; grupos alquileno tais como C <MU>= <MV>C ; e NH, N(C1-C3 alquila),O,S,C (O) CH2 e OCH2; R1 e R2 são independentemente selecionados do grupo consistindo de hidrogênio e uma alquila de cadeia reta ou ramificada C1-C8 ou cicloalquila C3-C8; R3 é uma alquila de cadeia reta ou ramificada; R4 é uma cicloalquila C3-C10 opcionalmente substituída com OH ou uma cicloalquila opcionalmente substituída com OH, e R8 é uma alquila de cadeia reta ou ramificada ou uma cicloalquila C3-C8 opcionalmente substituída com OH. (.c) reagir dito composto (IV) com uma quantidade efetiva de uma base para formar o composto (V) Onde Z é selecionado do grupo consistindo de grupos de alquileno tais como CH2, CH2CH2CH(CH3), grupos alquilenos tais como CH=CH; grupos alquileno tais como C <MU>= <MV> C; e NH, N (C1-C3 alquila),O,S,C (O) CH2 e OCH2; R1 e R2 são independentemente selecionados do grupo consistindo de hidrogênio e uma alquila de cadeia reta ou ramificada C1-C8 ou cicloalquila C3-C8; R3 é uma alquila de cadeia reta ou ramificada; R4 é uma cicloalquila C3-C10 opcionalmente substituída com OH ou uma cicloalquila opcionalmente substituída com OH, e R8 é uma alquila de cadeia reta ou ramificada ou uma cicloalquila C3-C8 opcionalmente substituída com OH. (d) reagir dito composto(V) com uma quantidade efetiva de um composto de desulfuração para formar o composto (VI) : onde Z é selecionado do grupo consistindo de grupos de alquileno tais como CH2, CH2CH2CH(CH3), grupos alquilenos tais como CH=CH; grupos alquileno tais como C <MU>= MV>C ; e NH, N(C1-C3 alquila),O,S,C (O) CH2 e OCH2; R1 e R2 são independentemente selecionados do grupo consistindo de hidrogênio e uma alquila de cadeia reta ou ramificada C1-C8 ou cicloalquila C3-C8; R3 é uma alquila de cadeia reta ou ramificada; R4 é uma cicloalquila C3-C10 opcionalmente substituída com OH ou uma cicloalquila opcionalmente substituída com OH, e R8 é uma alquila de cadeia reta ou ramificada ou uma cicloalquila C3-C8 opcionalmente substituída com OH.; e (e) submeter dito composto(VI) a etapas sucessivas de halogenação e deslocamento para formar dito composto.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6937197P | 1997-12-12 | 1997-12-12 | |
| PCT/US1998/026340 WO1999031105A1 (en) | 1997-12-12 | 1998-12-10 | 3-substituted adenines via2-thioxanthines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9815170A true BR9815170A (pt) | 2000-10-10 |
Family
ID=22088545
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9815170-3A BR9815170A (pt) | 1997-12-12 | 1998-12-10 | "método de obter composto aplicável no tratamento de asma em mamìferos" |
| BR9815169-0A BR9815169A (pt) | 1997-12-12 | 1998-12-11 | "método para formar um composto e composto aplicável no tratamento de asma em mamìferos, composição farmacêutica, método para efetivar a inibição seletiva de pde iv em mamìferos de estado de doença e método de tratar mamìfero sofrendo de estado de doença." |
| BR9815171-1A BR9815171A (pt) | 1997-12-12 | 1998-12-11 | Composto inibidor de pde iv aplicável no tratamento de doenças, particularmente de asma, em mamìferos e método para tratar um paciente sofrendo estados doentios. |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9815169-0A BR9815169A (pt) | 1997-12-12 | 1998-12-11 | "método para formar um composto e composto aplicável no tratamento de asma em mamìferos, composição farmacêutica, método para efetivar a inibição seletiva de pde iv em mamìferos de estado de doença e método de tratar mamìfero sofrendo de estado de doença." |
| BR9815171-1A BR9815171A (pt) | 1997-12-12 | 1998-12-11 | Composto inibidor de pde iv aplicável no tratamento de doenças, particularmente de asma, em mamìferos e método para tratar um paciente sofrendo estados doentios. |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US6037470A (pt) |
| EP (3) | EP1044201A4 (pt) |
| JP (5) | JP2002508378A (pt) |
| KR (3) | KR100349385B1 (pt) |
| CN (3) | CN1294590A (pt) |
| AT (1) | ATE244243T1 (pt) |
| AU (5) | AU1722999A (pt) |
| BR (3) | BR9815170A (pt) |
| CA (3) | CA2313004A1 (pt) |
| DE (3) | DE19882893T1 (pt) |
| DK (1) | DK1045849T3 (pt) |
| ES (1) | ES2202924T3 (pt) |
| GB (2) | GB2346878B (pt) |
| HU (3) | HUP0301166A2 (pt) |
| NO (1) | NO20002998L (pt) |
| PL (1) | PL341108A1 (pt) |
| PT (1) | PT1045849E (pt) |
| TR (1) | TR200001706T2 (pt) |
| WO (5) | WO1999031105A1 (pt) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6413975B1 (en) * | 1999-04-02 | 2002-07-02 | Euro-Celtique, S.A. | Purine derivatives having phosphodiesterase iv inhibition activity |
| EP1202628B1 (en) * | 1999-08-12 | 2004-10-13 | Euro-Celtique S.A. | Novel hypoxanthine and thiohypoxanthine compounds |
| US7342021B2 (en) * | 2001-02-08 | 2008-03-11 | Memory Pharmaceuticals Corp. | Phosphodiesterase 4 inhibitors |
| FR2842809A1 (fr) * | 2002-07-26 | 2004-01-30 | Greenpharma Sas | NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION |
| CA2494026A1 (en) * | 2002-08-08 | 2004-02-19 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors |
| CN1688580A (zh) * | 2002-08-08 | 2005-10-26 | 记忆药物公司 | 作为磷酸二酯酶4抑制剂的2－三氟甲基－6－氨基嘌呤衍生物 |
| US20040063938A1 (en) * | 2002-09-30 | 2004-04-01 | Pfizer Inc | Process for preparing haloalkyl pyrimidines |
| KR20070007759A (ko) * | 2003-07-10 | 2007-01-16 | 아칠리온 파르마세우티칼스 인코포레이티드 | 바이러스 복제 억제제로서 유용한 치환된 아릴티오우레아유도체 |
| TW200523262A (en) * | 2003-07-29 | 2005-07-16 | Smithkline Beecham Corp | Inhibitors of AKT activity |
| WO2005058898A2 (en) * | 2003-12-16 | 2005-06-30 | Ranbaxy Laboratories Limited | Purine compounds which can be used as phosphodiesterase (pde) type iv inhibitors |
| EP2258357A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| AU2006282896A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| WO2007047978A2 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| JP2009513672A (ja) | 2005-10-31 | 2009-04-02 | ブレインセルス，インコーポレイティド | 神経発生のｇａｂａ受容体媒介調節 |
| US7625890B2 (en) | 2005-11-10 | 2009-12-01 | Smithkline Beecham Corp. | Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| EP2377531A2 (en) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| MX2008014320A (es) | 2006-05-09 | 2009-03-25 | Braincells Inc | Neurogenesis mediada por el receptor de 5-hidroxitriptamina. |
| DE102006033572A1 (de) | 2006-07-20 | 2008-01-24 | Bayer Cropscience Ag | N'-Cyano-N-halogenalkyl-imidamid Derivate |
| US7998971B2 (en) | 2006-09-08 | 2011-08-16 | Braincells Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| UY30892A1 (es) * | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| BRPI0820791A2 (pt) | 2007-12-17 | 2015-06-16 | Lux Innovate Ltd | Composições e métodos para manutenção de sistemas de condução e contenção de fluido |
| UA106740C2 (uk) * | 2009-01-30 | 2014-10-10 | Глаксосмітклайн Ллс | Кристалічний гідрохлорид n-{(1s)-2-аміно-1-[(3-фторфеніл)метил]етил}-5-хлор-4-(4-хлор-1-метил-1h-піразол-5-іл)-2-тіофенкарбоксаміду |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| HRP20171665T1 (hr) * | 2011-12-28 | 2017-12-15 | Global Blood Therapeutics, Inc. | Supstituirani spojevi benzaldehida i metode za njihovu primjenu u povećanju oksigenacije tkiva |
| HK1203412A1 (en) | 2011-12-28 | 2015-10-30 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
| WO2013106547A1 (en) | 2012-01-10 | 2013-07-18 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
| US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| PE20161035A1 (es) | 2013-03-15 | 2016-11-13 | Global Blood Therapeutics Inc | Compuestos y usos de estos para la modulacion de la hemoglobina |
| US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| CA2902711C (en) | 2013-03-15 | 2021-07-06 | Global Blood Therapeutics, Inc. | Substituted pyridinyl-6-methoxy-2-hydroxybenzaldehyde derivatives and pharmaceutical compositions thereof useful for the modulation of hemoglobin |
| US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
| EP2970308B1 (en) | 2013-03-15 | 2021-07-14 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| AP2016009261A0 (en) | 2014-02-07 | 2016-06-30 | Global Blood Therapeutics Inc | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| DK3383392T3 (da) | 2015-12-04 | 2025-08-18 | Global Blood Therapeutics Inc | Doseringsskema for 2.HYDROXY.6.((2.(1.ISOPROPYL.1H.PYRAZOL.5.YL)PYRIDIN.3.YL)METHOXY)BENZALDEHYD |
| WO2017123766A1 (en) * | 2016-01-12 | 2017-07-20 | Sperovie Biosciences, Inc. | Compounds and compositions for the treatment of disease |
| TWI752307B (zh) | 2016-05-12 | 2022-01-11 | 美商全球血液治療公司 | 新穎化合物及製造化合物之方法 |
| TW202332423A (zh) | 2016-10-12 | 2023-08-16 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
| US11014884B2 (en) | 2018-10-01 | 2021-05-25 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin |
| RU2746012C2 (ru) * | 2019-05-13 | 2021-04-05 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации ФГБОУ ВО ВолгГМУ МЗ РФ | Антидепрессантное средство для коррекции нежелательных побочных эффектов нейролептиков |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2844577A (en) * | 1958-07-22 | Certificate of correction | ||
| US2956998A (en) | 1960-10-18 | Adenine derivatives and process | ||
| US3215696A (en) * | 1965-11-02 | Substituted adenines -and preparation thereof | ||
| US2903455A (en) | 1959-09-08 | Jdnviiiiaisnvhi jo | ||
| US2697709A (en) | 1951-06-14 | 1954-12-21 | Burroughs Wellcome Co | Mercapto heterocycles and method of making |
| US2691654A (en) | 1952-06-11 | 1954-10-12 | Buroughs Wellcome & Co U S A I | Amino heterocycles and method of making |
| US2966488A (en) | 1956-07-30 | 1960-12-27 | Shive William | Substituted alkylaminopurines |
| US2957875A (en) | 1957-11-18 | 1960-10-25 | Upjohn Co | Derivatives of purine |
| US3079378A (en) | 1960-02-01 | 1963-02-26 | Upjohn Co | Acylated psicofuranosyladenines |
| BE601946A (pt) * | 1960-03-31 | |||
| US3135753A (en) | 1961-05-10 | 1964-06-02 | Burroughs Wellcome Co | Alkylthiopurines and method |
| FR1548252A (pt) | 1961-10-13 | 1968-12-06 | ||
| IL24679A (en) * | 1965-11-24 | 1971-10-20 | Yissum Res Dev Co | Derivatives of 3-methyl purine and methods of preparing the same |
| US3669979A (en) | 1967-12-14 | 1972-06-13 | Gaf Corp | Novel process for the production of 2-benzothiazolyl-phenol and derivatives thereof employing phosphorus trichloride as a catalyst |
| US3952001A (en) | 1970-07-01 | 1976-04-20 | The Boots Company Limited | 1-Carbamoyl-1,2,4-triazoles |
| JPS5121529A (ja) | 1974-08-16 | 1976-02-20 | Hitachi Ltd | Pirorinsandometsukizeiseihimakuboshiho |
| USRE31429E (en) | 1977-02-14 | 1983-10-25 | Merck & Co., Inc. | Process for preparation of 9-(dihalobenzyl)adenines |
| GB2041359B (en) * | 1979-01-10 | 1982-12-15 | Ici Ltd | Purine derivatives and their use in the defoliation of cotton plants |
| US4241063A (en) | 1979-08-06 | 1980-12-23 | Bristol-Myers Company | Purine derivatives and their use as bronchodilators |
| US4361699A (en) | 1981-09-28 | 1982-11-30 | Merck & Co., Inc. | Novel process for the preparation of N6 -alkyl-arprinocid |
| US4407802A (en) | 1981-09-28 | 1983-10-04 | Merck & Co., Inc. | 6-Amidino-9-substituted benzyl purines |
| GB2120065B (en) | 1982-04-27 | 1986-01-02 | Michael Frederick Huber | Heating plants |
| US4492592A (en) | 1983-06-06 | 1985-01-08 | Shell Oil Company | Combined desiccation of substantially supercritical CO2 |
| JPS60260579A (ja) | 1984-01-13 | 1985-12-23 | Yoshitomi Pharmaceut Ind Ltd | プリン誘導体 |
| US4883801A (en) | 1984-09-07 | 1989-11-28 | The General Hospital Corporation | Xanthine derivative pest control agents |
| GB8510758D0 (en) | 1985-04-27 | 1985-06-05 | Wellcome Found | Compounds |
| FI875724A7 (fi) | 1986-04-29 | 1987-12-28 | Pfizer | Kalsiumista riippumaton cAMP fosfodiesteraasi-inhibiittori-masennukse nvastainen lääke. |
| GB8618931D0 (en) | 1986-08-02 | 1986-09-10 | Euro Celtique Sa | 6-thioxanthines |
| US5057517A (en) | 1987-07-20 | 1991-10-15 | Merck & Co., Inc. | Piperazinyl derivatives of purines and isosteres thereof as hypoglycemic agents |
| US5091431A (en) | 1988-02-08 | 1992-02-25 | Schering Corporation | Phosphodiesterase inhibitors |
| EP0363320A3 (de) | 1988-10-06 | 1991-11-21 | Ciba-Geigy Ag | Substituierte 9H-Purine |
| US4971972A (en) | 1989-03-23 | 1990-11-20 | Schering Corporation | Phosphodiesterase inhibitors having an optionally substituted purine derivative portion and a benzo- or cyclopenta-furan portion |
| US5290782A (en) | 1989-09-01 | 1994-03-01 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine derivatives |
| ATE195739T1 (de) | 1989-10-20 | 2000-09-15 | Kyowa Hakko Kogyo Kk | Kondensierte purinderivate |
| US5117830A (en) | 1990-11-08 | 1992-06-02 | Whitby Research, Inc. | Method of determining viability of tissue |
| US5177074A (en) | 1991-03-26 | 1993-01-05 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted thiophene or furan |
| JP3264492B2 (ja) | 1992-01-13 | 2002-03-11 | スミスクライン・ビーチャム・コーポレイション | ピリジル置換イミダゾール |
| IL104369A0 (en) | 1992-01-13 | 1993-05-13 | Smithkline Beecham Corp | Novel compounds and compositions |
| ES2102036T3 (es) | 1992-06-15 | 1997-07-16 | Celltech Therapeutics Ltd | Derivados con grupo fenilo trisustituido utilizados como inhibidores selectivos de la fosfodiesterasa iv. |
| EP0652868B1 (en) | 1992-07-28 | 2004-11-10 | Aventis Pharma Limited | INHIBITORS OF c-AMP PHOSPHODIESTERASE |
| GB9222253D0 (en) | 1992-10-23 | 1992-12-09 | Celltech Ltd | Chemical compounds |
| ATE234270T1 (de) | 1992-12-02 | 2003-03-15 | Pfizer | Cathecoldiether als selektive pde iv hemmungsmittel |
| GB9226830D0 (en) | 1992-12-23 | 1993-02-17 | Celltech Ltd | Chemical compounds |
| TW263495B (pt) | 1992-12-23 | 1995-11-21 | Celltech Ltd | |
| GB9304919D0 (en) | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
| GB9304920D0 (en) | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
| DE4309969A1 (de) | 1993-03-26 | 1994-09-29 | Bayer Ag | Substituierte heteroanellierte Imidazole |
| GB9312853D0 (en) * | 1993-06-22 | 1993-08-04 | Euro Celtique Sa | Chemical compounds |
| FI951367A7 (fi) | 1994-03-28 | 1995-09-29 | Japan Energy Corp | Puriinijohdannaiset ja tulehdustautien tukahduttajat (suppressantit) |
| US5869486A (en) | 1995-02-24 | 1999-02-09 | Ono Pharmaceutical Co., Ltd. | Fused pyrimidines and pyriazines as pharmaceutical compounds |
-
1998
- 1998-12-10 DE DE19882893T patent/DE19882893T1/de not_active Withdrawn
- 1998-12-10 WO PCT/US1998/026340 patent/WO1999031105A1/en not_active Ceased
- 1998-12-10 JP JP2000539027A patent/JP2002508378A/ja active Pending
- 1998-12-10 AU AU17229/99A patent/AU1722999A/en not_active Abandoned
- 1998-12-10 US US09/209,658 patent/US6037470A/en not_active Expired - Lifetime
- 1998-12-10 EP EP98962064A patent/EP1044201A4/en not_active Withdrawn
- 1998-12-10 JP JP2000539026A patent/JP2002508377A/ja active Pending
- 1998-12-10 GB GB0013780A patent/GB2346878B/en not_active Expired - Fee Related
- 1998-12-10 BR BR9815170-3A patent/BR9815170A/pt not_active Application Discontinuation
- 1998-12-10 KR KR1020007005963A patent/KR100349385B1/ko not_active Expired - Fee Related
- 1998-12-10 GB GB0013781A patent/GB2346879B/en not_active Expired - Fee Related
- 1998-12-10 JP JP2000539028A patent/JP2002508379A/ja active Pending
- 1998-12-10 WO PCT/US1998/026338 patent/WO1999031103A1/en not_active Ceased
- 1998-12-10 HU HU0301166A patent/HUP0301166A2/hu unknown
- 1998-12-10 AU AU17228/99A patent/AU1722899A/en not_active Abandoned
- 1998-12-10 US US09/209,922 patent/US6040447A/en not_active Expired - Lifetime
- 1998-12-10 CA CA002313004A patent/CA2313004A1/en not_active Abandoned
- 1998-12-10 US US09/209,664 patent/US6057445A/en not_active Expired - Fee Related
- 1998-12-10 AU AU17230/99A patent/AU1723099A/en not_active Abandoned
- 1998-12-10 DE DE19882892T patent/DE19882892T1/de not_active Withdrawn
- 1998-12-10 WO PCT/US1998/026339 patent/WO1999031104A1/en not_active Ceased
- 1998-12-10 CN CN98812098A patent/CN1294590A/zh active Pending
- 1998-12-11 CN CN98813362A patent/CN1284077A/zh active Pending
- 1998-12-11 DE DE69816127T patent/DE69816127T2/de not_active Expired - Fee Related
- 1998-12-11 PL PL98341108A patent/PL341108A1/xx unknown
- 1998-12-11 US US09/210,556 patent/US6228859B1/en not_active Expired - Fee Related
- 1998-12-11 BR BR9815169-0A patent/BR9815169A/pt not_active Application Discontinuation
- 1998-12-11 US US09/210,557 patent/US6211367B1/en not_active Expired - Lifetime
- 1998-12-11 CN CN98812064A patent/CN1281458A/zh active Pending
- 1998-12-11 CA CA002314335A patent/CA2314335A1/en not_active Abandoned
- 1998-12-11 AT AT98963053T patent/ATE244243T1/de not_active IP Right Cessation
- 1998-12-11 HU HU0100417A patent/HUP0100417A3/hu unknown
- 1998-12-11 JP JP2000539025A patent/JP3504234B2/ja not_active Expired - Fee Related
- 1998-12-11 WO PCT/US1998/026444 patent/WO1999029694A1/en not_active Ceased
- 1998-12-11 CA CA002313150A patent/CA2313150A1/en not_active Abandoned
- 1998-12-11 KR KR1020007006328A patent/KR20010032979A/ko not_active Withdrawn
- 1998-12-11 TR TR2000/01706T patent/TR200001706T2/xx unknown
- 1998-12-11 AU AU18159/99A patent/AU747366B2/en not_active Ceased
- 1998-12-11 EP EP98963053A patent/EP1045849B1/en not_active Expired - Lifetime
- 1998-12-11 AU AU18208/99A patent/AU1820899A/en not_active Abandoned
- 1998-12-11 BR BR9815171-1A patent/BR9815171A/pt not_active Application Discontinuation
- 1998-12-11 KR KR1020007006407A patent/KR20010033049A/ko not_active Withdrawn
- 1998-12-11 ES ES98963053T patent/ES2202924T3/es not_active Expired - Lifetime
- 1998-12-11 WO PCT/US1998/026293 patent/WO1999031102A1/en not_active Ceased
- 1998-12-11 EP EP98963114A patent/EP1045850A4/en not_active Withdrawn
- 1998-12-11 DK DK98963053T patent/DK1045849T3/da active
- 1998-12-11 PT PT98963053T patent/PT1045849E/pt unknown
- 1998-12-11 JP JP2000524287A patent/JP2001525412A/ja active Pending
- 1998-12-11 HU HU0100305A patent/HUP0100305A2/hu unknown
-
2000
- 2000-06-09 NO NO20002998A patent/NO20002998L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9815170A (pt) | "método de obter composto aplicável no tratamento de asma em mamìferos" | |
| NO20000325L (no) | Absorbentsammensetning for rensing av gasser som inneholder sure komponenter | |
| FR2828487B1 (fr) | Nouveaux composes derives d'acides gras, preparation et utilisations | |
| NO20012411L (no) | Pyrrolidin-derivater-CCR-3-reseptorantagonister | |
| KR920008122A (ko) | 히드록시 아릴트리아진 및 테트라알킬 피페리딘을 함유하는 상승적 안정제 조성물 및 이로써 중합체를 안정화하는 방법 | |
| ATE281481T1 (de) | Zusammensetzungen, enthaltend aminische antioxidantien auf basis von n-(4- anilinophenyl)amiden | |
| BR0111230A (pt) | Composto, e, uso e processo para a preparação do mesmo | |
| ATE327994T1 (de) | Meso-substituierte tripyrrane derivate, zusammensetzungen und verwendungsmöglichkeiten sowie verfahren zu deren herstellung | |
| MXPA02008228A (es) | Metodo para la preparacion de citalopram. | |
| BRPI0511814A (pt) | método de inibir manchamento quìmico de uma superfìcie dental, e, composição para cuidado oral | |
| TW200500430A (en) | Crosslinking composition | |
| BR9713322A (pt) | Composição e método para tratamento de plantas com substâncias quìmicas exógenas | |
| DE3583362D1 (de) | Organopolysiloxane mit si-gebundenem wasserstoff und sic-gebundenen epoxygruppen, verfahren zu ihrer herstellung und eine verwendung dieser organopolysiloxane. | |
| PT83234B (pt) | Processo para a preparacao de derivados de indolina e de composicoes farmaceuticas que os contem | |
| BR0311469A (pt) | Composto de monÈmero que compreende diversos grupos catiÈnicos e polìmeros que compreendem unidades obtidas a partir deste | |
| ATE14014T1 (de) | Neue arylamin-derivate, verfahren zu deren herstellung und deren verwendung als mikrobizide. | |
| ATE239701T1 (de) | Polyethoxylierte retinamid-derivate und verfahren zu ihrer herstellung | |
| BR8601792A (pt) | Composicao de esmalte de unha e processo para a preparacao da mesma | |
| BRPI0408797A (pt) | composição de reticulação, processo para a produção da composição de reticulação, e, composição curável | |
| ATE55109T1 (de) | Chemisches verfahren zur herstellung von abkoemmlingen von oxamid. | |
| DE3767132D1 (de) | Polyfluorierte verbindungen und verfahren zu deren herstellung. | |
| TW200617048A (en) | Stabilized crosslinking composition | |
| BR0004764A (pt) | Compostos inibidores da reanimação de ciano-indol serotonina, um processo para sua preparação e composições farmacêuticas que os contêm | |
| EA200300029A1 (ru) | Новые соединения карбамат и тиокарбамат подофиллотоксина, способ их получения и содержащие их фармацевтические композиции | |
| AR010523A1 (es) | Composicion detergente que contiene una enzima celulitica y un tensioactivo cationico y un metodo para lavar la ropa en una lavadoradomestica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |